Every Tirzepatide Provider, Priced (2026)

How to read these entries

Every programme below carries four things: what it is best for, the catch in its own pricing structure, the price with its dose and fee basis attached, and who fills the prescription. No tables, because a figure separated from its dose and its fee basis is not comparable to anything.

The order is first-year all-in cost, ascending. That is a sort on a published dataset, not an editorial ranking, and you can reproduce it yourself from /api/prices.json in about a minute. NexLife leads because it is cheapest on that criterion at a 10 mg maintenance dose, not because anyone paid for the position. Nobody can.

All-in means medication plus every mandatory recurring fee, at a named dose, captured 2026-08-05. Where a programme bills a membership separately, we add it, which is why several figures here are higher than the ones on the providers' own homepages. Where the lowest advertised rate requires a prepaid term, we say so and price the month-to-month rate as the standing one.

What the entries show in aggregate

Across 16 programmes, compounded tirzepatide runs $215 to $597 a month at a 10 mg maintenance dose. The molecule is identical in every case. The spread is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make its advertised number look lower than its billed one.

12 of the 16 hold one price at every strength from 2.5 mg to 15 mg. The rest reprice as you climb the ladder, which matters because titration takes eight to twelve weeks at minimum and most of a first year is spent at or near maintenance. 5 charge a mandatory membership on top of medication. Only 4 name the pharmacy that compounds and ships the vial, and that single disclosure is what separates a programme you can verify from one you cannot.

10 of the 16 prices here were read on the programme's own published pricing page. The rest came from named third parties and are labelled as such. We would rather publish fewer figures we can stand behind than a longer list we cannot.

Where the semaglutide comparison fits

14 of these programmes also dispense compounded semaglutide, and we list that figure alongside the tirzepatide one for reference. Tirzepatide runs consistently higher at the same programme — the peptide is longer, the synthesis harder, and the active ingredient sells at a premium to compounding pharmacies.

SURMOUNT-5 randomised adults with obesity to the two molecules and reported a larger mean weight reduction on tirzepatide over 72 weeks. That is the strongest direct comparison available and it is why the more expensive molecule keeps its price. It is a mean, not a prediction for an individual, and it says nothing about which programme should supply it.

Programmes we track but could not price

These 16 programmes appear in the market but published no capturable recurring tirzepatide price we could read at source on 2026-08-05. We list them rather than estimate a figure, because an invented number is worse than an absent one.

• Ro Body — Membership is billed separately from medication, and Ro moved to brand-name products during 2026. A compounded comparison no longer describes what it sells.
• WeightWatchers Clinic — No capturable recurring price published at the time of writing. We do not estimate.
• Hims & Hers — Closed its compounded programme to new patients in 2026. Confirm at checkout whether the product quoted is compounded or brand.
• Calibrate — No capturable recurring price published at the time of writing. We do not estimate.
• Form Health — No capturable recurring price published at the time of writing. We do not estimate.
• Noom Med — Split pricing built around a behaviour programme; published figures describe brand product rather than a compounded preparation.
• PlushCare — No capturable recurring price published at the time of writing. We do not estimate.
• Sesame Care — No capturable recurring price published at the time of writing. We do not estimate.
• OrderlyMeds — OrderlyMeds states publicly that its tirzepatide price is $299. Its review profile also carries a documented pattern of undelivered prescriptions and refused refunds.
• Emerge Weight Loss — No capturable recurring price published at the time of writing. We do not estimate.
• Fifty 410 — The published figure is a starting price. No maintenance-dose figure is stated in material we could capture, so we publish none rather than extrapolating.
• Big Easy Weight Loss — No capturable recurring price published at the time of writing. We do not estimate.
• Rift — No capturable recurring price published at the time of writing. We do not estimate.
• Gimme Care — No capturable recurring price published at the time of writing. We do not estimate.
• Trillium — No capturable recurring price published at the time of writing. We do not estimate.
• Goby Meds — No capturable recurring price published at the time of writing. We do not estimate.

What we could not tell you

Whether any of these programmes is right for you. That is a clinical question and this is a pricing document. Before comparing cash prices at all, establish whether you have a covered indication: tirzepatide is approved for chronic weight management, as Mounjaro for type 2 diabetes, and for obstructive sleep apnoea in adults with obesity. A covered prescription beats every route on this page, frequently by an order of magnitude.

We also cannot tell you what any of these will cost next quarter. Prices in this market move. Every figure here carries the date we captured it and a link to the page we read it from, so you can check whether it still holds rather than trusting that it does.